

**Date and Time:** *Tuesday 4th November 2014 10:00 – 16:30*

**Minutes:** Confirmed

**Guideline Development Group Meeting Preterm labour and birth**

**Place:** *Royal College of Obstetricians and Gynaecologists  
London*

**Present:**

Jane Norman (JN) (Chair)	(Present for notes 1 – 9)
Judi Barratt (JB)	(Present for notes 1 – 9)
Paul Eunson (PE)	(Present for notes 1 – 9)
Jane Hawdon (JH)	(Present for notes 3 – 9)
Phillip Owen (PO)	(Present for notes 1 – 9)
Jane Plumb (JP)	(Present for notes 1 – 9)
Farah Pradhan (FP)	(Present for notes 1 – 9)
Marianne Rowntree (MR)	(Present for notes 1 – 9)
Meekai To (MT)	(Present for notes 1 – 9)
Martin Ward-Platt (MWP)	(Present for notes 1 – 9)
Louise Weaver-Lowe (LW-L)	(Present for notes 1 – 9)

**In attendance:**

NCC-WCH staff: Maryam Gholitabar (MG) Juliet Kenny (JK) David James (DJ) Paul Jacklin (PJ) Hugo Pedder (HP) Grammati Sarri (GS)		(Present for notes 1 – 9) (Present for notes 1 – 9) (Present for notes 1 – 9) (Present for notes 1 – 9) (Present for notes 7 – 9) (Present for notes 1 – 9)
NICE attendees: Oliver Bailey (OB) Steven Barnes (SB)		(Present for notes 1 – 9) (Present for notes 6 – 9)

**Observers:**

None		
------	--	--

**Notes**

- JN welcomed the group to the tenth meeting of this GDG. Apologies were received from Shona Burman-Roy.

JN asked all the GDG members and other attendees to declare any new interests that they had accrued since GDG 9 and reiterate any interests declared previously that were relevant to the meeting agenda.

JN

**Personal non-financial non-specific**

Member of the board of Equality Challenge Unit (a charity that aims to further and support

## Notes

equality and diversity for staff and students in higher education institutions across the UK and in colleges in Scotland).

### **Personal financial non-specific**

Receives funding to act as a member of a clinical advisory board of PDC Biotech developing a drug to delay or halt preterm labour (PDC31 - a synthetic octapeptide FP receptor modulator, which has been shown to induce uterine smooth muscle relaxation and delay parturition in preclinical studies).

Commented [GS1]: Awaiting final clarification

### **Non-personal financial non-specific**

Member of an independent data monitoring committee for a study of retosiban to treat preterm labour. The study is being undertaken by Glaxosmithkline and the company will reimburse Edinburgh University for any travel expenses incurred by JN while undertaking this work.

Commented [GS2]: Awaiting final clarification

### **JP**

#### **Non-personal financial non-specific**

Co-applicant on an HTA project comparing different strategies for Group B streptococcus prevention for women in term and preterm labour – no funds awarded yet.

2. The minutes of the last meeting were agreed with one amendment.
3. PJ gave a presentation updating the group on progress with the health economic analysis for diagnosis and treatment of women in suspected preterm labour (focussing on those aspects relating to tocolytic drug treatment). The draft model was displayed on screen. The GDG had the opportunity to ask questions and provide feedback on baseline probabilities and other aspects of the model design and to ask questions.
4. GS presented the revised review for information and support for women who are at risk of preterm labour or who are in suspected or diagnosed preterm labour (the protocol, the list of excluded studies, the evidence tables, the evidence profiles, evidence summary and draft recommendations). The group had an opportunity discuss the results and ask questions.
5. JN led the group through the process of interpreting the evidence and drafting recommendations. Notes were made live on screen.
6. HP presented the revised review for utility of fetal blood sampling (FBS) as an adjunct to intrapartum fetal heart rate monitoring at different gestational ages (the protocol, the list of excluded studies and evidence summary). The group had an opportunity discuss the results and ask questions.
7. MG presented the revised review for use of a fetal scalp electrode (FSE) for unborn babies of different gestation ages whose mothers are in diagnosed preterm labour (the protocol, the list of excluded studies and evidence summary). The group had an opportunity discuss the results and ask questions.
8. JN led the group through the process of interpreting the evidence and drafting recommendations for the FBS and FSE reviews. The group also reviewed and revised the draft recommendations for the reviews for criteria for interpreting the preterm fetal heart rate trace at different gestational ages for unborn babies whose mothers are in suspected or diagnosed preterm labour and electronic fetal monitoring versus intermittent auscultation in women who are in suspected or diagnosed preterm labour. Notes were made live on screen.
9. There was no other business. JN thanked the participants for attending and closed the meeting.

**Notes**

**Date, time and venue of the next meeting**

Friday 12<sup>th</sup> November 2014, 10:00 – 16:30 at the Royal College of Obstetricians and Gynaecologists, London.